Latest Articles
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace
Published: March 23, 2026, 12:47 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire
Published: March 23, 2026, 11:30 a.m.
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine
Published: Feb. 17, 2026, 12:15 a.m.
Predicted peptide scaffolds for drug screening in endometrial cancer organoids - Nature
Predicted peptide scaffolds for drug screening in endometrial cancer organoids Nature
Published: Oct. 27, 2025, 2:22 p.m.
Link copied to clipboard!